Comment on: Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 1, 2013, Pages 246-

  Kavi, Jay ^a   Bhattacharjee, Deepannita ^a   Macve, Joanna ^a   Weinbren, Michael J ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Bacteraemias; Blood cultures; Pharmacokinetics

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBAPENEMASE; CEFPODOXIME; CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BLOOD CULTURE; ENZYME ASSAY; ESCHERICHIA COLI INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; LETTER; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANIMALS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMASES; HUMANS;

EID: 84871224728     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks378     Document Type: Letter

References (4)

1. Livermore DM, Andrews JM, Hawkey PM et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012; 67: 1569-77.
2. Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Critical Care 2011; 15: R206.
3. BSAC. Resistance Surveillance Data. Bacteraemia Programme 2010. http://bsac.org.uk/surveillance/resistance-surveillance-data/(5 August 2012, date last accessed).
4. Weinbren MJ, Borthwick MA. Rapid detection of extended-spectrum β-lactamase (ESBL)-producing organisms in blood culture. J Antimicrob Chemother 2005; 55: 131-2.